Please login to the form below

Not currently logged in

Pharmaceutical Market Europe - February 2019

PME February

Welcome to the February issue of Pharmaceutical Market Europe

The very idea of being able to edit our genes still sounds like something from science fiction, but in 2019, it is now very much a scientific reality. That’s thanks to pioneers using technologies such as CRISPR, and this year sees the first CRISPR-based therapeutics entering clinical trials.

Nevertheless, there is still some way to go before these revolutionary technologies can prove themselves to be safe and effective – the recent setback to Sangamo Therapeutics’ zinc finger nuclease (ZFN) platform bearing testimony to that.

Read more about gene editing in our in-depth coverage starting on p19.

Before I go, a reminder that this year’s Communiqué Awards programme is now open for entries. I had the pleasure of hosting a special podcast with some of the awards’ judges. The podcast gives some pointers on what makes a winning campaign, so that should be well worth listening to for anyone looking to enter. You can find the podcast and details of the awards on our website,

View PME February 2019 online

Register here to receive email notification of future digital editions of PME or contact the subscriptions department to enquire about receiving a print copy of the magazine. More PMLiVE digital editions can be found here.

PME is also available to download as an app for iPhone and iPad

Please note: Some older digital editions may no longer be accessible while we transition to a new digital edition system and app -

COVID-19 Updates and Daily News

Featured jobs


Add my company
Page & Page and Partners

For those who can imagine better, Page & Page and Partners (P&P) is home to meaningful encounters of a marketing, communication...